National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
NCI Drug Dictionary
Page Options
Print This Page  Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

NCI Responds to Hurricanes

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

safingol
A saturated derivative of sphingosine. As an inhibitor of protein kinase C (PKC), safingol competitively binds to the regulatory phorbol-binding domain of PKC, a kinase involved in tumorigenesis. This agent has been shown to act synergistically with other chemotherapeutic agents and may potentiate chemotherapy drug-induced apoptosis in vitro and in vivo. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:Sphinganine
US brand name:Kynacyte
Chemical structure names:
  • 2-Amino-1,3-Dihydroxyoctadecane
  • L-threo-dihydrosphingosine



Previous:S-1, S-3304, S-adenosyl-L-methionine disulfate p-toluene-sulfonate, S-CKD602, sabarubicin
Next:Salagen, salinosporamide A, salirasib, salmonella VNP20009, Salvia officinalis extract tablet

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov